ADC Therapeutics stock gained 8.27 percent to USD 1.38

Published on 10/08/2026 at 04:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ADC Therapeutics stock saw 816,530 shares traded on October 7, 2026, while it sat 72.3 percent below its USD 4.98 yearly high. Q2 cash reached USD 219.1 million.

ADCT, CH0499880968, Illustration mit AI erstellt.

ADC Therapeutics (ISIN CH0499880968) was trading at USD 1.38 on the NYSE on October 7, 2026, at 1:15 p.m. ET, up 8.27 percent from the USD 1.27 prior close. The biotechnology company therefore entered the latest session at a market capitalization of USD 174.9 million.

Price remains below the yearly high

Trading volume reached 816,530 shares, while the intraday range ran from USD 1.24 to USD 1.41. The stock remained 72.3 percent below its 52-week high of USD 4.98 and stood USD 0.60 above its 52-week low of USD 0.78.

The price move is important because ADCT remains a small-cap biotechnology name with a wide trading range. Its latest market value was USD 174.9 million on October 7, 2026, while the 52-week range extended from USD 0.78 to USD 4.98.

Q2 revenue reached USD 19.2 million

According to Quartr in its Q2 2026 summary published September 10, 2026, total revenue reached USD 19.2 million, up 2.2 percent from the year-earlier quarter. Product revenue was USD 18.6 million, while cash and cash equivalents stood at USD 219.1 million as of June 30, 2026.

The same Q2 summary put the net loss at USD 16.6 million and adjusted operating expenses at USD 37.2 million, down 22 percent year over year. Operating cash outflow for the first six months was USD 41.5 million, compared with USD 80.4 million in the prior-year period.

Analysts keep a Hold consensus

MarketBeat reported on October 7, 2026, that six firms held a consensus Hold rating, with three Buy ratings, two Hold ratings and one Sell rating. The average 12-month price target was USD 5.00, leaving the stock price 72.4 percent below the consensus target.

MarketBeat also reported that ADC Therapeutics had posted adjusted quarterly loss per share of USD 0.11 against a consensus loss of USD 0.22 for Q2 2026. The result places the upcoming November 10, 2026 earnings date in view as the next scheduled checkpoint for the company.

ADCT stock stays in a wide range

ADC Therapeutics develops antibody-drug conjugates for cancer treatment, with ZYNLONTA as its lead commercial product. The combination of USD 19.2 million in Q2 revenue, USD 219.1 million in cash and a USD 4.98 yearly high gives investors three reference points for judging the USD 1.38 share price.